Wuhan Keqian Biological Co., Ltd. was founded in 2001 and listed on the Science and Technology Board of the Shanghai in 2020, with stock code 688526，focusing on the development, production, sales and veterinary technical services on animal vaccines, diagnostic reagents, biological therapeutic agents, antibodies and feed additives.
The company is a high-tech enterprise invested and established by scientific researchers from the Animal Infectious Diseases Laboratory of Huazhong Agricultural University. Keqian Bio has a research and development technical team led by academicians and a high-quality management and operation team.
The company is the first batch of enterprises to be awarded the title of "National High-tech Industrialization Demonstration Project" by the National Development and Reform Commission and was selected as a "China Famous Brand" enterprise. It was recognized as the "National Enterprise Technology Center" in 2020, and was selected as the "Top 100 Manufacturing Industries in Hubei Province" for two consecutive years in 2018 and 2019. With the strategic goal of "building national industrial brand and leading industrial development", the company adheres to the values of "creating value through science and technology and repaying society with science and technology". Staff stick to the "innovation, creation, entrepreneurship" spirit, the pursuit of "loyalty, enterprising, rigorous, pragmatic" attitude.
The company focuses on the research and development, production, sales of veterinary biological products and technical services for animal epidemic prevention. The products now cover a variety of vaccines and diagnostic reagents for pigs, poultry and pets. The company has won 2 second prizes of National Science and Technology Progress Award, 5 first prizes of Hubei Science and Technology Progress Award, 1 first prize of Hubei Science and Technology Achievement Promotion Award. It has won 38 national patents, 34registration certificates for new veterinary drugs, and 5 National Key New Products patents.
By virtue of professional integrity, wholehearted service and caring attitudes, Keqian Biology has won the trust of the majority of users and set up a good corporate image. The company is committed to becoming a world-class enterprise of animal health, regarding the creation of national premium brand as its own duty, scaling new heights of biotechnology so as to protect the sustainable development of stock breeding and human health.
| Full name | Wuhan Keqian Biological Co., Ltd |
|---|---|
| Abbreviations | Keqian Bio |
| Code | 688526 |
| Founded | 2001-01-11 |
| Listing | 2020-09-22 |
| Domicile | No.419, High-Tech 2nd Road, East Lake High-Tech Development Zone, Wuhan 430073. |
| Website | http://www.kqbio.com/ |
| wuhankqbio@kqbio.com | |
| STAR Theme | Biomedicine |
| CSRC Sector | Farming, forestry, animal husbandry & fishery |
| Has weighted voting rights structure? | No |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Earnings Per Share | 1.16 | 0.67 | 1.08 |
| R&D expenditure as a % of operating revenue | 7.01% | 9.33% | 6.48% |
| Operating Revenue | 843.23 | 507.51 | 735.30 |
| Net Income | 447.80 | 242.64 | 388.91 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Operating Revenue | 843.23 | 507.51 | 735.30 |
| Operating Costs | 145.19 | 106.14 | 114.52 |
| Operating Income | 524.31 | 279.05 | 451.90 |
| Pretax Income | 519.66 | 278.30 | 451.80 |
| Income Tax | 71.86 | 35.66 | 62.89 |
| Net Income | 447.80 | 242.64 | 388.91 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Assets | |||
| Current Assets-Total | 2,461.60 | 852.31 | 893.65 |
| Non-current Assets-Total | 649.32 | 519.15 | 336.20 |
| Total Assets | 3,110.92 | 1,371.46 | 1,229.85 |
| Liabilities | |||
| Current Liabilities-Total | 354.18 | 207.31 | 309.64 |
| Non-current Liabilities-Total | 48.22 | 45.17 | 43.87 |
| Total Liabilities | 402.40 | 252.48 | 353.51 |
| Stockholder's Equity | |||
| Share Capital | 1,568.83 | 427.09 | 427.09 |
| Retained Profits | 1,139.69 | 691.89 | 449.25 |
| Total Owners' Equity | 2,708.52 | 1,118.98 | 876.34 |
| 2020 | 2019 | 2018 | |
|---|---|---|---|
| Net Cash Flows-Operating | 400.14 | 154.89 | 351.83 |
| Net Cash Flows-Investing | -1,190.30 | -623.72 | 323.03 |
| Net Cash Flows-Financing | 1,205.72 | -85.75 | -120.72 |
| Name | No. of Shares Held (mn) | % of Shares Held |
|---|---|---|
| Wuhan Huazhong Agricultural University Asset Management(武汉华中农大资产管理公司) | 78.00 | 16.78% |
| Chen Huanchun | 70.86 | 15.24% |
| Jin Meilin | 36.68 | 7.89% |
| He Qigai | 33.17 | 7.13% |
| Wu Bin | 33.17 | 7.13% |
| Fang Liurong | 33.17 | 7.13% |
| Wu Meizhou | 28.59 | 6.15% |
| Ye Changfa | 27.51 | 5.92% |
| Muyuan Industrial Group Co., Ltd(牧原实业集团有限公司) | 16.80 | 3.61% |
| Xu Gaoyuan | 3.52 | 0.76% |
All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.
Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.
Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.